Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Brent N. Rexer, Ritwik Ghosh, Carlos L. Arteaga

Research output: Contribution to journalComment/debate

33 Citations (Scopus)

Abstract

A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

Original languageEnglish (US)
Pages (from-to)4518-4520
Number of pages3
JournalClinical Cancer Research
Volume15
Issue number14
DOIs
StatePublished - Jul 15 2009

Fingerprint

Phosphatidylinositol 3-Kinase
Mitogen-Activated Protein Kinase Kinases
Biomarkers
PTEN Phosphohydrolase
Breast Neoplasms
Transcriptome
Up-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of PI3K and MEK : It is all about combinations and biomarkers. / Rexer, Brent N.; Ghosh, Ritwik; Arteaga, Carlos L.

In: Clinical Cancer Research, Vol. 15, No. 14, 15.07.2009, p. 4518-4520.

Research output: Contribution to journalComment/debate

Rexer, Brent N. ; Ghosh, Ritwik ; Arteaga, Carlos L. / Inhibition of PI3K and MEK : It is all about combinations and biomarkers. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 14. pp. 4518-4520.
@article{ebc55a98f3594f7c9da799c85b8176eb,
title = "Inhibition of PI3K and MEK: It is all about combinations and biomarkers",
abstract = "A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.",
author = "Rexer, {Brent N.} and Ritwik Ghosh and Arteaga, {Carlos L.}",
year = "2009",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-09-0872",
language = "English (US)",
volume = "15",
pages = "4518--4520",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Inhibition of PI3K and MEK

T2 - It is all about combinations and biomarkers

AU - Rexer, Brent N.

AU - Ghosh, Ritwik

AU - Arteaga, Carlos L.

PY - 2009/7/15

Y1 - 2009/7/15

N2 - A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

AB - A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=68049102319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049102319&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0872

DO - 10.1158/1078-0432.CCR-09-0872

M3 - Comment/debate

C2 - 19584146

AN - SCOPUS:68049102319

VL - 15

SP - 4518

EP - 4520

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -